Alkermes (NASDAQ:ALKS) EVP Craig Hopkinson Sells 9,000 Shares of Stock

Alkermes plc (NASDAQ:ALKS) EVP Craig Hopkinson sold 9,000 shares of the business’s stock in a transaction that occurred on Monday, March 2nd. The shares were sold at an average price of $29.72, for a total value of $267,480.00. Following the sale, the executive vice president owned 89,389 shares of the company’s stock, valued at approximately $2,656,641.08. This represents a 9.15% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link.

Alkermes Trading Down 3.6%

Shares of ALKS traded down $1.06 during trading hours on Thursday, reaching $28.23. The stock had a trading volume of 182,879 shares, compared to its average volume of 2,035,937. The firm has a 50-day simple moving average of $31.60 and a 200 day simple moving average of $30.24. Alkermes plc has a 12 month low of $25.17 and a 12 month high of $36.32. The company has a market capitalization of $4.70 billion, a price-to-earnings ratio of 19.77, a P/E/G ratio of 7.28 and a beta of 0.53.

Alkermes (NASDAQ:ALKS) last released its quarterly earnings data on Wednesday, February 25th. The company reported $0.29 earnings per share for the quarter, missing the consensus estimate of $0.43 by ($0.14). Alkermes had a return on equity of 14.91% and a net margin of 16.37%.The business had revenue of $384.55 million for the quarter, compared to analyst estimates of $380.44 million. During the same quarter in the previous year, the company posted $1.05 EPS. The business’s quarterly revenue was down 10.6% on a year-over-year basis. Alkermes has set its FY 2026 guidance at -0.798–0.680 EPS. On average, equities analysts forecast that Alkermes plc will post 1.31 EPS for the current year.

Analysts Set New Price Targets

A number of equities analysts have issued reports on the company. Royal Bank Of Canada cut their price target on Alkermes from $47.00 to $45.00 and set an “outperform” rating for the company in a research note on Thursday, February 26th. Wells Fargo & Company lifted their target price on Alkermes from $37.00 to $43.00 and gave the company an “overweight” rating in a research report on Thursday, February 26th. Zacks Research downgraded Alkermes from a “strong-buy” rating to a “hold” rating in a report on Thursday, February 19th. Wall Street Zen cut Alkermes from a “buy” rating to a “hold” rating in a research note on Saturday, February 28th. Finally, HC Wainwright reaffirmed a “neutral” rating and set a $43.00 price objective on shares of Alkermes in a report on Thursday, February 26th. One analyst has rated the stock with a Strong Buy rating, twelve have assigned a Buy rating and five have issued a Hold rating to the company’s stock. Based on data from MarketBeat.com, Alkermes currently has an average rating of “Moderate Buy” and an average target price of $44.07.

Hedge Funds Weigh In On Alkermes

Hedge funds and other institutional investors have recently made changes to their positions in the stock. Sanctuary Advisors LLC increased its holdings in Alkermes by 2.7% during the fourth quarter. Sanctuary Advisors LLC now owns 12,141 shares of the company’s stock worth $340,000 after buying an additional 315 shares during the last quarter. PNC Financial Services Group Inc. grew its position in shares of Alkermes by 3.5% during the 4th quarter. PNC Financial Services Group Inc. now owns 10,326 shares of the company’s stock valued at $289,000 after acquiring an additional 351 shares during the period. Orion Porfolio Solutions LLC grew its position in shares of Alkermes by 4.5% during the 3rd quarter. Orion Porfolio Solutions LLC now owns 8,762 shares of the company’s stock valued at $263,000 after acquiring an additional 376 shares during the period. Horizon Investments LLC increased its stake in shares of Alkermes by 0.9% during the 3rd quarter. Horizon Investments LLC now owns 43,002 shares of the company’s stock worth $1,290,000 after purchasing an additional 387 shares during the last quarter. Finally, AMG National Trust Bank raised its holdings in shares of Alkermes by 0.6% in the 3rd quarter. AMG National Trust Bank now owns 60,175 shares of the company’s stock worth $1,805,000 after purchasing an additional 388 shares during the period. 95.21% of the stock is owned by hedge funds and other institutional investors.

Alkermes Company Profile

Alkermes plc is a biopharmaceutical company focused on developing innovative medicines to address unmet needs in the central nervous system (CNS). The company applies its proprietary drug delivery technologies and therapeutic expertise to advance treatments for addiction, schizophrenia, bipolar I disorder and depression. Alkermes’ portfolio includes both commercial products and a pipeline of investigational therapies designed to improve patient outcomes and support long-term disease management.

Alkermes’ commercial franchise features several approved products.